A National Cancer Institute of Canada Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer

Annals of Oncology

Volumn 12, Issue 7, 2001, Pages 919-922

  Knowling, M ^a   Browman, G ^a   Siu, L ^a   Khoo, K ^a   Cooke, A ^a   Tannock, I ^a   Klaassen, D ^a   Cripps, C ^a   Goss, G ^a   Matthews, S ^a   Clarke, R ^a   Seymour, L ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

5 fluorouracil; Advanced head and neck cancer; Dihydropyrimidine dehydrogenase; Eniluracil; Phase II

Indexed keywords

5 ETHYNYLURACIL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; AMNESIA; ANOREXIA; ARTICLE; BIOCHEMISTRY; CANADA; CANCER CENTER; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; DYSESTHESIA; EDEMA; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HEMATOLOGIC DISEASE; HUMAN; ILLNESS BEHAVIOR; INFECTION; LETHARGY; LEUKOPENIA; MALE; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY DYSFUNCTION; SQUAMOUS CELL CARCINOMA; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; VERTIGO; XEROSTOMIA;

EID: 0034910872     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011141530545     Document Type: Article

References (6)

1. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
2. Population study of dihydropyrimidine dehydrogenase in cancer patients
3. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
4. One-sample multiple testing procedure for phase II clinical trials
5. 776C85: Effect on renal elimination of 5-fluorouracil and uracil in cancer patients
6. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity